Podcasts about acc aha guideline

2023 ACC/AHA Guideline for the Management of Patients With Chronic Coronary Disease - Link Já agora... RCM eicosapente de etilo - Link Prémios MF's de Ouro - ⁠Link⁠ --- Nova Android & iOS app MGFamiliar - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Link⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Subscreva o Podcast MGFamiliar para não perder qualquer um dos nossos episódios. Além disso, considere deixar-nos uma revisão ou um comentário no Apple Podcasts ou no Spotify. --- Music Kind of a Party by Mini Vandals - Link

Join Drs Carol Wysham and Silvio Inzucchi as they discuss how type 2 diabetes management has evolved over the years, and the most promising developments on the horizon. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982419). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Continuous Glucose Monitoring in Persons With Type 2 Diabetes Not Using Insulin https://pubmed.ncbi.nlm.nih.gov/34633261/ Macrovascular Complications of Type 2 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/30961498/ Rate of Decline in Kidney Function and Known Age-of-Onset or Duration of Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/34282181/ Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/26378978/ Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/27299675/ Tirzepatide Prescribing Information https://uspl.lilly.com/mounjaro/mounjaro.html#pi Glycemic Targets: Standards of Care in Diabetes-2023 https://pubmed.ncbi.nlm.nih.gov/36507646/ 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines https://pubmed.ncbi.nlm.nih.gov/30879355/ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update https://pubmed.ncbi.nlm.nih.gov/35963508/ 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension https://pubmed.ncbi.nlm.nih.gov/30165516/ The Role of BNP Testing in Heart Failure https://pubmed.ncbi.nlm.nih.gov/17168346/ Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) Rationale and Design https://pubmed.ncbi.nlm.nih.gov/32916609/ A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL) https://clinicaltrials.gov/ct2/show/NCT03914326 GLP-1 Receptor Agonists and Kidney Protection https://pubmed.ncbi.nlm.nih.gov/31159279/ Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study https://pubmed.ncbi.nlm.nih.gov/31589290/ A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6) https://clinicaltrials.gov/ct2/show/NCT04537923 The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD https://pubmed.ncbi.nlm.nih.gov/34406410/ Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/19523535/ Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/30090738/

Episode 112: Statins in Primary CareDr. Tiwana explains the use of statins for the primary prevention of cardiovascular disease.Written by Ripandeep Tiwana, MD (Post-Doctoral Research Fellow at Cedar Sinai Medical Center – Heart Institute). Edition of text and comments by Hector Arreaza, MD.____________________________________________You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Definition.Statins commonly referred to as lipid-lowering medications, are important in primary care as they serve multiple long-term benefits than just lipid lowering alone. They are HMG-CoA reductase inhibitors. As a refresher, this is the rate-controlling enzyme of the metabolic pathway that produces cholesterol. This enzyme is more active at night, so statins are recommended to be taken at bedtime instead of during the day. Statins are most effective at lowering LDL cholesterol. However, they also help lower triglycerides and raise HDL cholesterol.Statins are not limited to just patients with hyperlipidemia. They reduce illness and mortality in those who have diabetes, have a history of cardiovascular disease (including heart attack, stroke, peripheral arterial disease), or are simply at high risk for cardiovascular disease. Statins are used for primary and secondary prevention.Types of statins.How do we determine which statin our patients need?First, we need to know that not all statins are created equal. They vary by intensity and potency thus, and they are categorized as either low, moderate, or high intensity.Several statins are available for use in the United States. They include Atorvastatin (Lipitor), Fluvastatin (Lescol XL), Lovastatin (Altoprev), Pitavastatin (Livalo, Zypitamag), Pravastatin (Pravachol), Rosuvastatin (Crestor, Ezallor), Simvastatin (Zocor)Commonly used in clinics: Simvastatin, Atorvastatin, and Rosuvastatin.Statin Dosing and ACC/AHA Classification of Intensity                                  Low-intensity                                   Moderate-intensity                                     High-intensityAtorvastatin              NA 1                                                          10 to 20 mg                                                   40 to 80 mgFluvastatin                20 to 40 mg                                          40 mg 2×/day; XL 80 mg                                NALovastatin                 20 mg                                                       40 mg                                                                         NAPitavastatin               1 mg                                                          2 to 4 mg                                                                   NARosuvastatin             NA                                                            5 to 10 mg                                                          20 to 40 mgSimvastatin                10 mg                                                      20 to 40 mg                                                             NAOf note, atorvastatin and rosuvastatin are only for moderate or high-intensity use, and do not use simvastatin 80 mg.Identifying patients at risk.How do we determine who needs statin therapy?Once we become familiar with the different statins, we must figure out which intensity is advised for our patient. Recommendations for statin therapy are based on guidelines from The U.S. Preventive Services Task Force (USPSTF), American Diabetes Association (ADA), and the American College of Cardiology/American Heart Association (ACC/AHA) which recommend utilizing the ASCVD risk calculator in those patients who do not already have established cardiovascular disease.ASCVD stands for atherosclerotic cardiovascular disease, defined as coronary heart disease, cerebrovascular disease, or peripheral arterial disease presumed to be of atherosclerotic origin. ASCVD remains a leading cause of morbidity and mortality in the United States, especially in individuals with diabetes.The ASCVD risk score determines a patient's 10-year risk of cardiovascular complications, such as a myocardial infarction or stroke. This risk estimate considers age, sex, race, cholesterol levels, use of blood pressure medication, diabetic status, and smoking status. Regarding age, this calculator only applies to the age range of 40-79 as there is insufficient data to predict risk outside this age group.There are several online and mobile applications available to calculate this score. Once calculated it gives a recommendation for which intensity statin to use. However, as this is a recommendation, it is essential to use your own clinical judgment to decide what is best for your individual patient. Please refer to the above table as a reference for which statin and dose you may consider using.Keeping the above calculator in mind, additional statin guidelines are recommended by the ACC:Patients ages 20-75 years and LDL-C ≥190 mg/dl use high-intensity statin without risk assessment. (You do not need the calculator.)People with type 2 diabetes and aged 40-75 years use moderate-intensity statins, and risk estimate to consider high-intensity statins. (It means moderate for all diabetics older than 40, high for some.)Age >75 years, clinical assessment, and risk discussion. Age 40-75 years and LDL-C ≥70 mg/dl and 10%. Grade B recommendation: prescribe a statin for the primary prevention of CVD.Grade C – 40-75 years with >= 1 cardiovascular risk factor AND estimated 10-year ASCVD risk 7.5-10%. Grade C recommendation: selectively offer a statin for the primary prevention of CVD. The likelihood of benefit is smaller in this group than in persons with a 10-year risk of 10% or greater.Grade I - The USPSTF found insufficient evidence to recommend for or against initiating a statin for the primary prevention of CVD events and mortality in adults 76 years or older.The USPSTF is also very clear regarding the intensity of statin therapy. They explained that there is limited data directly comparing the effects of different statin intensities on health outcomes. Most of the trials they reviewed used moderate-intensity statin therapy. They conclude that moderate-intensity statin therapy seems reasonable for most persons' primary prevention of CVD.The USPSTF has a broader recommendation, whereas the ACC guidelines are more detailed and individualized and provide guidance on the recommended intensity of statin therapy.Labs needed.Establish baseline labs for serum creatinine, LFTs, and CK only if there is a myopathy risk. Routine monitoring of LFTs, serum creatinine, and CK is unnecessary; only check if clinically indicated.A lipid panel should be checked in 6-8 weeks, and the patient should monitor themselves for any side effects, including myalgias. If LDL-C reduction is adequate (≥30% reduction with intermediate statins and 50% with high-intensity statins), regular interval monitoring of risk factors and compliance with statin therapy is necessary to sustain long-term benefit.Side effects and contraindications.Some common side effects include URI-like symptoms, headache, UTI, and diarrhea. Some patients are very hesitant to take any medications. Warning about side effects may decrease compliance. Major  contraindications for statin therapy include active liver disease, muscle disorders, pregnancy, and breastfeeding.Special considerations.Chronic kidney disease: The preferred statins for CKD with severe renal impairment are atorvastatin and fluvastatin because they do not require dose adjustment. Pravastatin would be a second choice.Chronic liver disease: Statins are contraindicated in patients with decompensated cirrhosis or acute liver failure. Abstinence from alcohol is critical in patients with chronic liver disease who are taking statins. Pravastatin and rosuvastatin are the preferred agents. Check lipid levels to determine if LDL-C reduction is accomplished with no changes in aminotransferases. You may consider stopping, increasing dose, or changing statin as you discuss the risks vs. benefits with your patient.Conclusion: Simply put, if a patient has an LDL of greater than 190, is a diabetic, has an established history of cardiovascular disease, or is at risk for it, then the patient should ideally be taking a statin unless there is a contraindication, allergy, or other special circumstance that limits him/her from doing so. If you have patients that apply to any of the above scenarios and are not already on a statin, determine their risk, and consider starting them on a statin “stat” to reduce morbidity and mortality. On the other hand, be mindful of overprescribing. Do not prescribe statins to patients who do not meet the above criteria.________________________________________Now we conclude our episode number 113, “Statins in Primary Care.” Statins are powerful medications for the prevention of cardiovascular disease. Do not forget to recommend non-pharmacologic measures such as healthy eating and physical activity, but let's also consider adding a statin to patients who are at moderate to high risk for cardiovascular disease.This week we thank Hector Arreaza and Ripandeep Tiwana. Audio by Adrianne Silva.Even without trying, every night, you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you; send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!______________________________________References:1. Statins, U.S. Food & Drug Administration, 2014, December 16, fda.gov, https://www.fda.gov/drugs/information-drug-class/statins, accessed September 14, 2022.2. Chou R, Cantor A, Dana T, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Aug. (Evidence Synthesis, No. 219.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK583661/3. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; March 17. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2019/03/07/16/00/2019-acc-aha-guideline-on-primary-prevention-gl-prevention. 4. ASCVD Risk Estimator Plus, published by the American College of Cardiology, https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/, accessed September 14, 2022.5. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication, U.S. Preventive Services Task Force, Final Recommendation Statement, 2022, August 23. https://uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication6.  Videvo. “Distinction.” Https://Www.videvo.net/Royalty-Free-Music-Track/Distinction/227882/, Https://Www.videvo.net/, https://www.videvo.net/royalty-free-music-track/distinction/227882/. Accessed 26 Sept. 2022.

Drs Stanley Cohen and Atul Deodhar discuss cardiovascular risk in patients with psoriatic arthritis and the impact of effective treatment. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970784). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Prevalence of Metabolic Syndrome in Psoriatic Arthritis: Systematic Literature Review and Results From the CARMA Cohort https://journals.lww.com/jclinrheum/Abstract/2022/03000/Prevalence_of_Metabolic_Syndrome_in_Psoriatic.22.aspx Metabolic Syndrome https://emedicine.medscape.com/article/165124-overview What Is the Framingham Risk Score (FRS)? https://www.medscape.com/answers/2500032-166149/what-is-the-framingham-risk-score-frs 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines https://www.sciencedirect.com/science/article/pii/S0735109713060312?via%3Dihub What Is the Systematic Coronary Risk Evaluation (SCORE)? https://www.medscape.com/answers/2500032-166154/what-is-the-systematic-coronary-risk-evaluation-score Anti-inflammatory Therapy With Canakinumab for Atherosclerotic Disease https://www.nejm.org/doi/pdf/10.1056/nejmoa1707914 Colchicine in Patients With Chronic Coronary Disease https://www.nejm.org/doi/10.1056/NEJMoa2021372 The Effects of Tumour Necrosis Factor Inhibitors, Methotrexate, Non-steroidal Anti-inflammatory Drugs and Corticosteroids on Cardiovascular Events in Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis https://ard.bmj.com/content/74/3/480 Psoriatic Arthritis Medication https://emedicine.medscape.com/article/2196539-medication Efficacy and Safety of Selective TYK2 Inhibitor, Deucravacitinib, in a Phase II Trial in Psoriatic Arthritis https://ard.bmj.com/content/81/6/815 FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death

Pyrlcasts, brought to you by Pyrls.com! We take a closer look at interesting and relevant clinical topics related to pharmacotherapy. Want to learn more clinical pearls? Boost your clinical confidence? Visit and sign-up for an account at pyrls.com to get over 10 high-quality charts absolutely FREE! Episode References: Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery [published correction appears in Circulation. 2016 Sep 6;134(10):e192-4]. Circulation. Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea?. Thromb Haemost. 2012;108(6):1031-1036. doi:10.1160/TH12-08-05472016;134(10):e123-e155. doi:10.1161/CIR.0000000000000404 Krakowiak A, Kuleta J, Plech I, et al. Ticagrelor-Related Severe Dyspnoea: Mechanisms, Characteristic Features, Differential Diagnosis and Treatment. Clin Med Insights Case Rep. 2020;13:1179547620956634. Published 2020 Oct 8. doi:10.1177/1179547620956634 Undem BJ, Kollarik M. The role of vagal afferent nerves in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):355-372. doi:10.1513/pats.200504-033SR PLAVIX- clopidogrel tablet, film coated. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Accessed via DailyMed. Updated March 5, 2021. BRILINTA- ticagrelor tablet. AstraZeneca Pharmaceuticals LP. Accessed via DailyMed. Updated May 9, 2022. PRASUGREL tablet, film coated. Accord Healthcare Inc. Accessed via DailyMed. Updated May 21, 2021.

This episode discusses things to consider beyond the severity when assessing aortic regurgitation using echocardiography. It includes references to ASE, EACVI, ESC and ACC guidelines.An echo education podcast.References referred to in the episode:1.      Lancellotti, P. et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. European Heart Journal - Cardiovascular Imaging. 2013; 14(7):–644, https://doi.org/10.1093/ehjci/jet1052.      Zoghbi et al. Recommendations for the Noninvasive Evaluation of Native Valvular Regurgitation. Journal of the American Society of Echocardiography. 2017; 30(4):303-371. https://www.onlinejase.com/article/S0894-7317(17)30007-X/fulltext3.       Vahanian, A. et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2021 https://doi.org/10.1093/eurheartj/ehab3954.       Otto, C. et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021; 143:e72-e227. https://doi.org/10.1161/CIR.0000000000000923

CardioNerds, Amit Goyal, Dr. Tommy Das (Program Director of the CardioNerds Academy and Cardiology fellow at Cleveland Clinic), Dr. Rick Ferraro (Director of CardioNerds Journal Club and Cardiology fellow at the Johns Hopkins Hospital), Dr. Patrick Zakka (CardioNerds Academy Chief fellow of House Jones and Cardiology fellow at UCLA) discuss omega-3 fatty acids & the battle of the oils with Dr. Pam Taub, Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center and Professor of Medicine at UC San Diego. Learn all about the different types of omega-3 fatty acids and the differences between prescription omega-3 fatty acids and dietary supplement fish oils. Audio editing by CardioNerds Academy Intern, Shivani Reddy. This episode is part of the CardioNerds Lipids Series which is a comprehensive series lead by co-chairs Dr. Rick Ferraro and Dr. Tommy Das and is developed in collaboration with the American Society For Preventive Cardiology (ASPC). Relevant disclosures: None Pearls • Notes • References • Guest Profiles • Production Team CardioNerds Cardiovascular Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - Omega-3 Fatty Acids & The Battle Of The Oils Coming soon! Show notes - Omega-3 Fatty Acids & The Battle Of The Oils Coming soon! References - Omega-3 Fatty Acids & The Battle Of The Oils Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Circulation. 2019 Sep 10;140(11):e649-e650] [published correction appears in Circulation. 2020 Jan 28;141(4):e60] [published correction appears in Circulation. 2020 Apr 21;141(16):e774].Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Circulation. 2019 Jun 18;139(25):e1182-e1186]. Circulation. 2019;139(25):e1082-e1143.Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk [published correction appears in Atherosclerosis. 2020 Jan;292:160-162] [published correction appears in Atherosclerosis. 2020 Feb;294:80-82]. Atherosclerosis. 2019;290:140-205.Bhatt D, Steg P, Miller M et al., 2019. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England journal of medicine, 380(1), pp.11–22.Budoff M, Bhatt D, Kinninger A et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925-3932.Nicholls S, Lincoff A, Garcia M et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268-2280. Guest Profiles Dr. Pam Taub Dr. Pam Taub, Professor of Medicine, is the founding director of the StepFamily Foundation Cardiac Rehabilitation and Wellness Center at the University of California, San Diego. Dr. Taub is a leader in preventive cardiology and has authored over one hundred publications, abstracts and book chapters. Dr. Taub is a leader in multiple professional societies, including board membership for the American Society of Preventive Cardiology. Dr. Patrick Zakka Dr. Patrick Zakka completed his medical school at th...

CardioNerds Rounds Co-Chairs, Dr. Karan Desai and Dr. Natalie Stokes and CardioNerds Academy Fellow, Dr. Najah Khan, join Dr. Martha Gulati – President-Elect of the American Society for Preventive Cardiology (ASPC) and prior Chief of Cardiology and Professor of Medicine at the University of Arizona – to discuss challenging cases in cardiac prevention. As an author on numerous papers regarding cardiac prevention and women's health, Dr. Gulati provides many prevention pearls to help guide patient care. Come round with us today by listening to the episodes now and joining future sessions of #CardsRounds! This episode is supported with unrestricted funding from Zoll LifeVest. A special thank you to Mitzy Applegate and Ivan Chevere for their production skills that help make CardioNerds Rounds such an amazing success. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. Case details are altered to protect patient health information. CardioNerds Rounds is co-chaired by Dr. Karan Desai and Dr. Natalie Stokes.  Speaker disclosures: None Cases discussed and Show Notes • References • Production Team CardioNerds Rounds PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Show notes - Challenging Cases of Challenging Cases of Cardiovascular Prevention with Dr. Martha Gulati Case #1 Synopsis: A 55-year-old South Asian woman presents to prevention clinic for an evaluation of an elevated LDL-C. Her prior history includes hyperlipidemia, hypertension, obesity, and pre-eclampsia. She was told she had “high cholesterol” a few years prior and would need medication. She started exercising regularly and cut out sweets from her diet. Before clinic, labs showed: Total Cholesterol (mg/dL) of 320, HDL 45, Triglycerides 175, and (directly measured) LCL-C 180. Her Lipoprotein(a) is 90 mg/dL (ULN being ~ 30 mg/dL). Her HbA1C is 5.2% and her 10-year ASCVD Risk (by the Pooled Cohorts Equation) is 5.4%. Her recent CAC score was 110. She prefers not to be on medication and seeks a second opinion. Takeaways from Case #1 As Dr. Gulati notes, in the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, South Asian ethnicity is considered a “risk enhancing factor.” The pooled cohort equations (PCE) may underestimate risk in South Asians. Furthermore, risk varies within different South Asian populations, with the risk for cardiovascular events seemingly higher in those individuals of Bangladeshi versus Pakistani or Indian origin. There are multiple hypotheses for why this may be the case including cultural aspects, such as diet, physical activity, and tobacco use. A better understanding of these factors could inform targeted preventive measures.In the same 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease mentioned above, history of an adverse pregnancy outcome (APO) increases later ASCVD risk (e.g., preeclampsia) and is also included as a “risk-enhancing factor.” Studies have shown that preeclampsia is an independent risk factor for developing early onset coronary artery calcification. Recent data has shown that the risk for developing preeclampsia is not the same across race and ethnicity, with Black women more likely to develop preeclampsia. Black women also had the highest rates of peripartum cardiomyopathy, heart failure, and acute renal failure. After adjustment for socioeconomic factors and co-morbidities, preeclampsia was associated with increased risk of CVD events in all women, the risk was highest among Asian and Pacific Islander women. Listen to Episode #174. Black Maternal Health with Dr. Rachel Bond to learn more about race-based disparities in cardio-obstetric care and outcomes.Our patient thus has multiple risk-enhancing factors to help in shared decision making and personalize her decisio...

In Episode #181 I sit down with physician and lipid specialist Dr Spencer Nadolsky to talk about cholesterol, ketogenic diets and cardiovascular disease. Specifically we cover: Spencer's background and journey to becoming a doctor What lipids are What lipoproteins are What causes atherosclerosis The difference between Apo B and LDL What evidence is there that atherosclerosis is caused by raised Apo B containing lipoproteins What is driving the denial of cholesterol's association with cardiovascular disease Dr Spencer's pilot study of diet-induced hypercholesterolemia Dr Spencer's tips for reducing risk of atherosclerosis Resources: Dr Nadolsky's blog on Cholesterol Code Dr Nadolsky on Twitter and Instagram Consensus Guideline Papers on preventing Atherosclerosis and/or Cardiovascular Disease LDL-C causes cardiovascular disease part 1 LDL-C causes cardiovascular disease part 2 2019 ESC/EAS Guidelines for the management of dyslipidaemias 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Want to support the show? If you are enjoying the Plant Proof podcast a great way to support the show is by leaving a review on the Apple podcast app. It only takes a few minutes and helps more people find the episodes. It's also helpful to subscribe on Apple Podcast app and/or follow on the Spotify Podcast app. Simon Hill, Nutritionist, Sports Physiotherapist Creator of Plantproof.com and host of the Plant Proof Podcast Author of The Proof is in the Plants Connect with me on Instagram and Twitter Download my FREE two week meal plan Download my FREE blood test and supplement guides here

In Episode #181 I sit down with physician and lipid specialist Dr Spencer Nadolsky to talk about cholesterol, ketogenic diets and cardiovascular disease.Specifically we cover:Spencer's background and journey to becoming a doctorWhat lipids areWhat lipoproteins areWhat causes atherosclerosisThe difference between Apo B and LDLWhat evidence is there that atherosclerosis is caused by raised Apo B containing lipoproteinsWhat is driving the denial of cholesterol's association with cardiovascular diseaseDr Spencer's pilot study of diet-induced hypercholesterolemiaDr Spencer's tips for reducing risk of atherosclerosisResources:Dr Nadolsky's blog on Cholesterol CodeDr Nadolsky on Twitter and InstagramConsensus Guideline Papers on preventing Atherosclerosis and/or Cardiovascular DiseaseLDL-C causes cardiovascular disease part 1LDL-C causes cardiovascular disease part 22019 ESC/EAS Guidelines for the management of dyslipidaemias2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease2021 ESC Guidelines on cardiovascular disease prevention in clinical practiceWant to support the show?If you are enjoying the Plant Proof podcast a great way to support the show is by leaving a review on the Apple podcast app. It only takes a few minutes and helps more people find the episodes.It's also helpful to subscribe on Apple Podcast app and/or follow on the Spotify Podcast app.Simon Hill, Nutritionist, Sports PhysiotherapistCreator of Plantproof.com and host of the Plant Proof PodcastAuthor of The Proof is in the PlantsConnect with me on Instagram and TwitterDownload my FREE two week meal planDownload my FREE blood test and supplement guides here

CardioNerds Dr. Rick Ferraro, Director of the #CardsJC Journal Club and cardiology fellow at Johns Hopkins, and Dr. Tommy Das, Program Director of the CardioNerds Academy and cardiology fellow at Cleveland Clinic, learn all about the clinical application of the ASCVD primary and secondary prevention guidelines in terms of lifestyle modifications and lipid lowering strategies from Dr. Allison Bailey, Editor-in-Chief of the ACCEL Audio Journal and Advanced Heart Failure and Transplant Cardiologist at Centennial Heart. Dr. Baily was a co-author on the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. In this episode we will learn about the current guidelines for primary prevention of ASCVD, the evidence for specific dietary changes in improving cardiovascular outcomes, the current guidelines for secondary prevention of ASCVD, how successful are clinicians and patients in meeting LDL-C recommendations, and what the recent SAMSON trial teaches us about statin intolerance. If you're a current internal medicine resident, interested in the intersection between medical education, cardiovascular disease and digital media, consider applying to the CardioNerds Academy using this link. The deadline for this application is October 15th 2021. Learn more by visiting the CardioNerds Academy page. Relevant disclosure: None Pearls • Notes • References • Guest Profiles • Production Team CardioNerds Lipid Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Qoatables - Lipid Lowering with Dr. Alison Bailey “Lifestyle should be the first step and the last step of everything we do.” Pearls - Lipid Lowering with Dr. Alison Bailey In patients without established clinical ASCVD, the percent reduction in LDL-C is the strongest predictor of cardiovascular benefit. In patients with high LDL-C levels, a 50% reduction in LDL-C levels should be targeted.In high-risk patients with established clinical ASCVD, we should target a 50% reduction in LDL-C levels and an LDL-C level less of than

In honor of February, Heart Health Month, we are recasting our favorite conversations with heart health experts!In this episode Laurence S. Sperling, M.D., FACC, FAHA, FACP, FASPC talks about prevention of heart disease. Dr. Sperling covers a range of topics related to cardiovascular disease and its prevention. What is preventive cardiology? How can we prevent heart disease in individuals and populations? What are the risk factors for heart disease? Dr. Sperling discusses the opportunities in healthcare as it relates to cardiovascular health, and why this topic is especially relevant in the time of the pandemic. Dr. Sperling talks about local and national projects he is leading to restore cardiovascular health and closes with tips on what each of us can do to make an impact. Tune in to learn more!Laurence S. Sperling, M.D., FACC, FAHA, FACP, FASPC is the current Executive Director of the Million Hearts Initiative for the Division of Heart Disease and Stroke Prevention at the Centers for Disease Control and Prevention and the Center for Medicare and Medicaid Services. He is the Founder and was the Director of The Heart Disease Prevention Center at Emory since 1997.  He is currently the Katz Professor in Preventive Cardiology at the Emory University School of Medicine, and Professor of Global Health in the Rollins School of Public Health. He served as the President of the American Society for Preventive Cardiology from 2014-2016, served on the writing committee of 2018 the ACC/ AHA Guideline on the Management on Blood Cholesterol, and served as Chair of the World Heart Federation writing group on the Roadmap for Cardiovascular Disease Prevention among People Living with Diabetes. Dr. Sperling was the recipient of the 2017 Award of Honor from the Alumni Association of Emory University School of Medicine. He has received awards for excellence in teaching (including 4 Golden Apple Awards and The Dean's Teaching Award), mentorship (Emory SOM 2018 Mentorship Award), and the R. Wayne Alexander Research mentor award. He has authored over 350 manuscripts/ abstracts/ books, and has been an invited speaker on every continent except Antarctica. This podcast is brought to you by Emory Lifestyle Medicine & Wellness. To learn more about our work, please visithttps://bit.ly/EmoryLM

In this episode, Michael Mack, MD, MACC, Kim Eagle, MD, MACC, and Rebecca Hahn, MD, FACC, discuss important changes in the 2020 valvular guideline update.

The CardioNerds discuss Lipid Management with Dr. Ann Marie Navar and Dr. Nishant Shah from Duke Medical Center, Division of Cardiology. Amit, Carine and Dan take a deep dive into the greasy world of lipids and cholesterol, covering lipid metabolism, therapeutic targets, approach across the entire spectrum of predicted risk, and key common management scenarios (statin intolerance, hypertriglyceridemia, elevated LP(a)), and more. Episode 42. Lipids and Cholesterol with Drs. Drs. Ann Marie Navar and Nishant Shah Take me to the Cardionerds Cardiovascular Prevention PageTake me to episode topics page The Cardionerds CV prevention series will include in-depth deep dives on so many topics related to prevention starting with this case discussion. Stay tuned for upcoming episodes on the ABCs of prevention, obesity, hypertension, diabetes mellitus and anti-diabetes agents, personalized risk and genetic risk assessments, hyperlipidemia, women’s cardiovascular prevention, coronary calcium scoring and so much more! Key references: Toth, P. P. (2020). Familial Hypercholesterolemia and Lipoprotein(a): Unraveling the Knot That Binds Them. Journal of the American College of Cardiology, 75(21), 2694–2697.Michos, E. D., McEvoy, J. W., & Blumenthal, R. S. (2019). Lipid management for the prevention of atherosclerotic cardiovascular disease. New England Journal of Medicine, 381(16), 1557–1567. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 73(24), e285–e350.Lloyd-Jones, D. M., Braun, L. T., Ndumele, C. E., Smith, S. C., Sperling, L. S., Virani, S. S., & Blumenthal, R. S. (2019). Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report from the American Heart Association and American College of Cardiology. Circulation, 139(25), E1162–E1177.Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020). Clinical review on triglycerides. European Heart Journal, 41(1), 99–109.ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 74(10), 1376–1414. We are truly honored to be producing the Cardionerds CVD Prevention Series in collaboration with the American Society for Preventive Cardiology! The ASPC is an incredible resource for learning, networking, and promoting the ideals of cardiovascular prevention! This series is kicked off by a message from Dr. Amit Khera, President of the American Society for Preventive Cardiology and President of the SouthWest Affiliate of the American Heart Association. Cardionerds Cardiovascular Prevention Series Dr. Ann Marie Navar is a cardiologist and epidemiologist at the Duke Clinical Research Institute focusing on cardiovascular disease prevention. She received an MD from Duke University and a PhD in Global Disease Epidemiology and Control from the Johns Hopkins School of Public Health in 2009 before completing residency in internal medicine and pediatrics and fellowship in cardiology at Duke. Dr. Navar’s research focuses on improving cardiovascular disease prevention through better identification of at-risk populations, targeted interventions to improve quality of care and patient engagement through the electronic health record, and better treatment of hypertension and cholesterol to lower CV risk. She also studies the impact of payer-imposed barriers to novel therapies. Her areas of expertise include risk prediction, patient risk communication, real world data analyses using EHR- and claims-based datasets, and registries. She is an associate editor at JAMA-Cardiology and a board membe...

This is a very special episode - Episode # 100! THANK YOU to everyone for your continued support!In this episode Laurence S. Sperling, M.D., FACC, FAHA, FACP, FASPC talks about prevention of heart disease. Dr. Sperling covers a range of topics related to cardiovascular disease and its prevention. What is preventive cardiology? How can we prevent heart disease in individuals and populations? What are the risk factors for heart disease? Dr. Sperling discusses the opportunities in healthcare as it relates to cardiovascular health, and why this topic is especially relevant in the time of the pandemic. Dr. Sperling talks about local and national projects he is leading to restore cardiovascular health and closes with tips on what each of us can do to make an impact. Tune in to learn more!Laurence S. Sperling, M.D., FACC, FAHA, FACP, FASPC is the current Executive Director of the Million Hearts Initiative for the Division of Heart Disease and Stroke Prevention at the Centers for Disease Control and Prevention and the Center for Medicare and Medicaid Services. He is the Founder and was the Director of The Heart Disease Prevention Center at Emory since 1997.  He is currently the Katz Professor in Preventive Cardiology at the Emory University School of Medicine, and Professor of Global Health in the Rollins School of Public Health. He served as the President of the American Society for Preventive Cardiology from 2014-2016, served on the writing committee of 2018 the ACC/ AHA Guideline on the Management on Blood Cholesterol, and served as Chair of the World Heart Federation writing group on the Roadmap for Cardiovascular Disease Prevention among People Living with Diabetes. Dr. Sperling was the recipient of the 2017 Award of Honor from the Alumni Association of Emory University School of Medicine. He has received awards for excellence in teaching (including 4 Golden Apple Awards and The Dean's Teaching Award), mentorship (Emory SOM 2018 Mentorship Award), and the R. Wayne Alexander Research mentor award. He has authored over 350 manuscripts/ abstracts/ books, and has been an invited speaker on every continent except Antarctica. This podcast is brought to you by Emory Lifestyle Medicine & Wellness. To learn more about our work, please visithttps://bit.ly/EmoryLM

In Episode 93 I sit back down with Sean Ryan to check in and see how he's been going with his transition to a plant based lifestyle. We pick up from where we left things in Episode 88, review his pre-transition baseline blood work and then spend the majority of the episode dedicated to the walking through cholesterol and how we can use diet to effect our cholesterol levels. At the end we also touch on meal prep, handling social conversations and a few other questions that Sean had since our last episode together. Whether you are thinking about transitioning to a plant-based diet, are currently transitioning or already eat a plant-based diet I think you will take something away from both today's episode and Episode 88. Episode Resources: 1 - 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk 2 - 2020 Consensus paper from European Atherosclerosis Society Consensus Panel stating that LDL lipoproteins cause atherosclerosis (narrowing of the artery) 3 - ACC guidelines - 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Recommends people adopt a Mediterranean or Plant-based diet for cardiovascular health. 4 - Garden of Vegan Meal Delivery Service (Australian based) Nutrikynd Supplement From time to time I am asked what supplements I take. The only supplement I currently take is the Nutrikynd Essential 3 which combines B12, Omega 3 and Vitamin D. Plant Proof X Journey Retreat For more information on the July 11-17, 2020 Plant Proof X Journey Retreat please visit here.The retreats are an incredible week - a mix of exercise, connecting with like-minded people, guest speakers, cooking demonstrations, delicious plant-based meals and snacks, massages and plenty of downtime to relax by the pool or explore the local area. As always, I hope you do enjoy the listen. If you did please share your feedback on social media, both Sean and I would love to hear from you. And of course, share the episode link with anyone you know that could benefit from listening. Finally, if you can take a minute or so to leave a review on the Apple podcast app it would be much appreciated. Thank you for tuning in friends. I appreciate all of you. See you next week. Simon

It's American Heart Month!  There is arguably no are of nutrition science that is more dynamic and ambiguous than that of heart health.  One day eggs are bad, the next day you should eat more. One day Statins should be in the water, the next day maybe they aren't great for everyone.  One day we should be counting our saturated fat grams, the next day we should be adding lard to our food. What gives? Today we will hopefully clear up the facts and give you some practical advice for keeping the most important muscle in your body thriving. Patreon | Love what you're hearing? Help fund ongoing episodes through donations as little as $1/month. Learn more here! Leave a review | When you leave a five star iTunes review, it helps others with similar interests and passions find us when they're looking for new content. Thank you in advance! Resources and Show Notes ASCVD 10-Year Risk Estimatory (for those 40+) 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease Carbohydrates and LDL Particle Size Statins, should you take them? The AHA Recommendations for Heart Health Triglyceride/HDL Ratios (aim for less than 3, or closer to 1, they say. Gina thinks this will become more important to cardiologists in years to come!) Cholesterol Clarity, by Jimmy Moore -Gina read this book and while she wasn't sold on all they had to say (for example, promoting bacon over chicken breast, no, just no) it was full of good research to support the idea that heart risk may have more to do with carbohydrate intake than once thought (especially for those at higher risk and with a propensity towards higher blood sugars). Also discusses different labs to focus on other than just total cholesterol an LDL. Good Calories Bad Calories - another book Gina read several years ago, full of really good information that might get you thinking. Favorite New Recipes or Products Slow Cooker Tater Tot Taco Casserole Kale Chips: Buy the already chopped and washed kale, lay out on a pan, spray with some oil, top with salt and pepper, heat at about 400-425 for 15-25 minutes (check regularly, and mix half way)

In Episode 93 I sit back down with Sean Ryan to check in and see how he's been going with his transition to a plant based lifestyle. We pick up from where we left things in Episode 88, review his pre-transition baseline blood work and then spend the majority of the episode dedicated to the walking through cholesterol and how we can use diet to effect our cholesterol levels. At the end we also touch on meal prep, handling social conversations and a few other questions that Sean had since our last episode together.Whether you are thinking about transitioning to a plant-based diet, are currently transitioning or already eat a plant-based diet I think you will take something away from both today's episode and Episode 88.Episode Resources:1 - 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk2 - 2020 Consensus paper from European Atherosclerosis Society Consensus Panel stating that LDL lipoproteins cause atherosclerosis (narrowing of the artery)3 - ACC guidelines - 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Recommends people adopt a Mediterranean or Plant-based diet for cardiovascular health.4 - Garden of Vegan Meal Delivery Service (Australian based)Nutrikynd SupplementFrom time to time I am asked what supplements I take. The only supplement I currently take is the Nutrikynd Essential 3 which combines B12, Omega 3 and Vitamin D. Plant Proof X Journey RetreatFor more information on the July 11-17, 2020 Plant Proof X Journey Retreat please visit here.The retreats are an incredible week - a mix of exercise, connecting with like-minded people, guest speakers, cooking demonstrations, delicious plant-based meals and snacks, massages and plenty of downtime to relax by the pool or explore the local area.As always, I hope you do enjoy the listen. If you did please share your feedback on social media, both Sean and I would love to hear from you. And of course, share the episode link with anyone you know that could benefit from listening.Finally, if you can take a minute or so to leave a review on the Apple podcast app it would be much appreciated.Thank you for tuning in friends. I appreciate all of you. See you next week.Simon

In this podcast, Donna Arnett, PhD, MSPH, and Roger Blumenthal, MD, who were co-chairs of the writing committee for the “2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease,” answer our questions about the updated guideline and why aspirin is no longer recommended. More at: www.consultant360.com/cardiology.

Read the transcript In this third episode, Ivor Cummins, Chief Program Manager of Irish Heart Disease Awareness (IHDA), shares why as a top class engineer he’s been decoding the causes of human chronic disease and obesity. He relates why orthodox healthcare is unnecessarily putting our health and lives at risk. He imparts what we can do ourselves to predict and prevent modern disease. Topics we discussed in this episode Ivor’s blood chemistry showing high serum ferritin, Gamma-Glutamyl Transferase (GGT) and cholesterol Ivor’s inability to get answers about the root cause of the high markers, nor any quantification of any increased morbidity or mortality His search for answers and the answer itself His serendipitous discovery that the risk markers used by orthodox healthcare are weak let alone optimal, even deeply misleading Better risk markers for morbidity and mortality prediction Serendipitously meeting David Bobbett who also had an axe to grind with orthodox healthcare after he discovered using his own efforts that he was very high risk, after being told he was low risk by healthcare The use of generic risk factor algorithms by orthodox healthcare and why they are not good enough Medications are often a very weak intervention e.g. little effect on all-cause mortality Correct diet and lifestyle is a more powerful intervention as it addresses the root cause Dietary root causes - primarily refined sugars, refined carbohydrates and vegetable oils (the three building blocks of manufactured “food like” products) Mixture of refined carbohydrates and fats is the least optimum for longevity and healthspan There is no more important factor in weight loss and longevity than your insulin status The bar where orthodox healthcare puts diabetes and diabetic physiology is very late in the diabetic journey, whereas it could be caught 15 years earlier The majority of the American adult population have diabetic physiology; the majority share this single metabolic disease Most doctors are not aware of insulin resistance outside the context of diabetes nor aware of insulin as a disease cause, only a medication Diabetic physiology is linked to fatty liver, obesity, heart disease, Alzheimer’s, many cancers; in fact all modern chronic diseases Orthodox healthcare is using glucose to determine diabetic status, whereas it should be using insulin, particularly post-prandial insulin Use of HOMA calculation as a cheap yet better measure of diabetic physiology Use of Kraft-Assay as the gold standard to measure of diabetic physiology Total cholesterol is a very poor risk marker LDL, the “bad” cholesterol is a very poor independent risk marker High resolution LDL analysis (LIPOPRINT/NMR) Bypassing fuzzy risk markers and guesses by using the Coronary Calcium Score (CAC) to see the disease directly The four types of people - it’s the metabolically unhealthy, thin outside, fat inside (TOFI) at the four who are most risk The orthodox intervention, low fat diets and vegetable oils, will probably just hasten your demise. Nutritional guidelines have been based upon junk science and have only exacerbated chronic disease and obesity Show links Irish Heart Disease Awareness (IHDA) Website Jeffry Gerber, MD Website Ivor Cummins Website Eat Rich, Live Long: Mastering the Low-Carb & Keto Spectrum for Weight Loss and Longevity Book David Bobbett on Independent.ie Rich List Web Page Coronary Calcium Score Web Page How Could a fit 51-year-old Have a 25pc Chance of a Massive Heart Attack Within a Year? Article Atherosclerosis Wikipedia Entry Framingham Risk Score Wikipedia Entry Framingham Risk Score Calculator Web Page Adipose Tissue Wikipedia Entry 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk Report ACC/AHA 2013 Cardiovascular Risk Assessment Calculator Web Page The Top 10 Causes of Death - WHO Web Page

Commentary by Dr. Valentin Fuster

Hypertension: everything you need to know about the new 2017 AHA/ACC guidelines This podcast covers the implications of the new 2017 ACC/AHA guidelines for clinicians and their patients, including changes to the definition of hypertension, self monitoring, management and new recommendations in relation to existing guidelines. Dr Jeffrey Brettler is a general internist who practices at the Kaiser Permanente West Los Angeles Medical Center and is the author of the BMJ Best Practice topic, Essential Hypertension. Dr Brettler is interviewed by Dr Alison Walker, a Clinical Editor for BMJ Best Practice and BMJ Learning. To learn more about Hypertension, visit BMJ Best Practice (bestpractice.bmj.com/topics/en-gb/26). 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (acc.org/guidelines#doctype=Guidelines) _ The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

We return to the topic of dyslipidemia and examined the: “2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults” http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a Previous episodes on statins can be found here. Major differences between AHA 2013 guideline and CCS 2012 guideline: CCS 2012 AHA 2013 Treatment Threshold LR (FRS